# Effect of Ruboxistaurin on Clinically Significant Macular Edema

> **NCT00133952** · PHASE3 · COMPLETED · sponsor: **Chromaderm, Inc.** · enrollment: 309 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Ruboxistaurin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00133952
- **Lead sponsor:** Chromaderm, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 309 (ACTUAL)
- **Last updated:** 2016-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00133952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00133952, "Effect of Ruboxistaurin on Clinically Significant Macular Edema". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00133952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*